MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.

被引：0

作者：

Mateos, Maria-Victoria

Bahlis, Nizar J.

Costa, Luciano J.

Perrot, Aurore

Pei, Lixia

Rubin, Maria L.

Lantz, Kristen

Sun, Weili

Jaffe, Mindy

Kobos, Rachel

Nooka, Ajay K.

机构：

[1] Hosp Clin Univ Salamanca, Salamanca, Spain

[2] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[3] Univ Alabama Birmingham, Birmingham, AL USA

[4] Ctr Hosp Univ Toulouse, Serv Hematol, Toulouse, France

[5] Janssen Res & Dev, Raritan, NJ USA

[6] Janssen Res & Dev, Spring House, PA USA

[7] Janssen Res & Dev, Los Angeles, CA USA

[8] Emory Univ, Winship Canc Inst, Atlanta, GA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8072

引用

页数：1

共 50 条

[1] MajesTEC-9: A randomized phase 3 study of teclistamab versus pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Touzeau, Cyrille
Hungria, Vania T. M.
Bhutani, Divaya
Landgren, Ola
Vieyra, Diego
Guo, Yue
Verona, Raluca
Miao, Xin
Qi, Mia
Watkins, Latisha
Shah, Priya
Chastain, Katherine
Qi, Ming
Quach, Hang
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph W.
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen J.
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Raymond
Wang, Jianping
Nottage, Kerri
Chiu, Christopher
Khokhar, Nushmia Z.
Ahmadi, Tahamtan
Lonial, Sagar
[J]. BLOOD, 2017, 130 (08) : 974 - 981
[3] Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
He, Jianming
Berringer, Heather
Heeg, Bart
Kampfenkel, Tobias
Dwarakanathan, Harikumaran R.
Johnston, Stephen
Mendes, Joao
Lam, Annette
Bathija, Sacheeta
Mackay, Eric
[J]. BLOOD, 2021, 138
[4] Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naive Relapsed Refractory Multiple Myeloma Patients
Ouchveridze, Evguenia
Singh, Chandandeep
Atrash, Shebli
Paul, Barry
Mohan, Meera
Alkharabsheh, Omar
Afrough, Aimaz
Cui, Wei
Mahmoudjafari, Zahra
Abdallah, Al-Ola
Hashmi, Hamza
[J]. BLOOD, 2022, 140 : 7164 - 7165
[5] EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma
Lonial, Sagar
Berdeja, Jesus G.
Dimopoulos, Meletios-Athanasios
Jagannath, Sundar
Knop, Stefan
Quach, Hang
Rodriguez-Otero, Paula
Richardson, Paul G.
Sorrell, April
Chen, Min
Kueenburg, Elisabeth
Tuong Vi Nguyen
Hong, Kevin
Peluso, Teresa
van de Donk, Niels W. C. J.
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S150 - S150
[6] PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
Palumbo, A.
Chanan-Khan, A.
Weisel, K.
Nooka, A. K.
Masszi, T.
Beksac, M.
Spicka, I.
Hungria, V.
Munder, M.
Mateos, M. V.
Mark, T.
Qi, M.
Schecter, J.
Amin, H.
Qin, X.
Deraedt, W.
Ahmadi, T.
Spencer, A.
Sonneveld, P.
[J]. HAEMATOLOGICA, 2016, 101 : 340 - 341
[7] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
Yee, Andrew J.
Nadeem, Omar
Rosenblatt, Jacalyn
Bianchi, Giada
O'Donnell, Elizabeth
Branagan, Andrew R.
Harrington, Cynthia C.
Agyemang, Emerentia A.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette A.
Bernstein, Zachary S.
Lyons, Rebecca T.
Riadi, Manal
Rowell, Sean M.
Mcvey, Cailin
Goguen, Amy C.
Horick, Nora K.
Richardson, Paul G.
Raje, Noopur S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naive Relapsed Multiple Myeloma
Afrough, Aimaz
Atrash, Shebli
Paul, Barry
Ouchveridze, Evguenia
Ahmed, Nausheen
Mahmoudjafari, Zahra
Bashir, Anam
Alkharabsheh, Omar
Hashmi, Hamza
Abdallah, Al-Ola
[J]. CANCERS, 2023, 15 (19)
[9] Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
Spencer, Andrew
Lentzsch, Suzanne
Weisel, Katja
Avet-Loiseau, Herve
Mark, Tomer M.
Spicka, Ivan
Masszi, Tamas
Lauri, Birgitta
Levin, Mark-David
Bosi, Alberto
Hungria, Vania
Cavo, Michele
Lee, Je-Jung
Nooka, Ajay K.
Quach, Hang
Lee, Cindy
Barreto, Wolney
Corradini, Paolo
Min, Chang-Ki
Scott, Emma C.
Chanan-Khan, Asher A.
Horvath, Noemi
Capra, Marcelo
Beksac, Meral
Ovilla, Roberto
Jo, Jae-Cheol
Shin, Ho-Jin
Sonneveld, Pieter
Soong, David
Casneuf, Tineke
Chiu, Christopher
Amin, Himal
Qi, Ming
Thiyagarajah, Piruntha
Sasser, A. Kate
Schecter, Jordan M.
Mateos, Maria-Victoria
[J]. HAEMATOLOGICA, 2018, 103 (12) : 2079 - 2087
[10] Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma
Dima, Danai
Mansour, Razan
Davis, James A.
Minchak, Megan
Goel, Utkarsh
Atallah, Rawan
Logan, Emerson
Tabak, Carine
Rashid, Aliya
Ahmed, Nausheen
Abdallah, Al-Ola
Hashmi, Hamza
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (06) : 975 - 983

← 1 2 3 4 5 →